Neonatal Estimation Of Brain Damage Risk And Identification of

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

NEOBRAIN brings together small and medium sized enterprises (SMEs), industry and academic groups devoted to the diagnosis, management, and neuroprotection in newborns with perinatal brain damage. The focus of NEOBRAIN is to identify strategies prevention of brain damage mainly observed in preterm newborns. (Copy from www.neobrain.eu)

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT02810626` - DTI & Tractography in Pediatric Tumor Surgery	N/A
Recruiting	`NCT02637817` - MRI-based Biomarkers for Predicting Punctate White Matter Lesions in Neonates
Terminated	`NCT01602276` - The Effect of tDCS on Subcortical Brain Functioning	N/A
Completed	`NCT03625570` - Power Training Combined With Interval Treadmill Training	N/A

NCT number	NCT00544895
Study type	Observational
Source	Hannover Medical School
Contact
Status	Completed
Phase	N/A
Start date	October 2007
Completion date	October 2010

Neonatal Estimation Of Brain Damage Risk And Identification of Neuroprotectants — NEOBRAIN

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms